- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01981733
Improving Lower Limb Blood Flow in Healthy Adult Volunteers (THRIVE-1)
November 5, 2013 updated by: Queen Mary University of London
A Study to Determine the Effects of a Novel Method for Improving Lower Limb Blood Flow in Healthy Adult Volunteers
The THRIVE-1 study will examine novel methods for enhancing blood flow in the lower limb using electrical stimulation.
Increases in lower limb blood flow improve venous return and thereby reduce venous stasis.
Since stasis is one of the compounding factors in the development of deep vein thrombosis, the risk of developing thrombosis should theoretically be proportionally reduced.
This technique may prove to be a useful tool in preventing and reducing the incidence of deep vein thrombosis in both medical and surgical patients together with passengers undertaking significant duration travel (as travel - related deep vein thrombosis is not exclusively related to flying).
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, EC1A 7BE
- St. Bartholomew's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be in good general health and fitness.
- Aged between 18 and 65 years.
- Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders or indications), screening physical examination, vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) and duplex ultrasound within 48 hours prior to commencement of the each study phase.
- BMI between 18 and 34
- No history or signs of drug abuse (including alcohol), licit or illicit.
- Has not to used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the thirty (30) days preceding the study, and agrees not to use any medications during the course of the study without informing the Research Team.
- Able to understand the Volunteer Information Sheet and signed the written Informed Consent Forms.
- Able and willing to follow the Protocol requirements.
Exclusion Criteria:
- Any evidence of organ dysfunction, or any clinically significant deviation from normal in the physical determinations.
- History or signs of haematological disorders (especially in relation to clotting or coagulation or previous Deep or superficial vein thrombosis/pulmonary embolism).
- Peripheral arterial disease (ABPI < 0.9), varicose veins or lower limb ulceration.
- Musculoskeletal disorders (such as pain during exercise of lower limb).
- Recent surgery (such as abdominal, gynaecological, hip knee replacement).
- Recent trauma to lower limb.
- Chronic Obesity (BMI Index >34).
- Pregnancy.
- Any Medication judged to be significant by the Principal Investigator (such as anticoagulants, agents with significant vasoactive activity, Oestrogen pill, 'morning-after pill' or HRT).
- Tobacco consumption
- History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, endocrine, neurological, dermatological, rheumatologic, metabolic (including diabetes), psychiatric, haematological (especially in relation to clotting or coagulation), or systemic disease judged to be significant.
- A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure >160 or <80 mmHg and/or a sitting diastolic pressure of >90 or <60 mmHg.
- Any significant illness during the four (4) weeks preceding the screening period of the study.
- Any contraindication to blood sampling.
- Donation of blood during the eight (8) weeks preceding the screening period of the study or during the investigation.
- Participation in any clinical study during the 8 weeks preceding the dosing period of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Device
|
The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in blood flow and volume, together with microcirculatory velocity were measured
Time Frame: 30 mins with 10 min washouts
|
Changes in blood flow and volume, together with microcirculatory velocity were measured using laser Doppler flowmetry (Laser Doppler Perfusion & Temperature Monitor DRT4; Moor Instruments Ltd, UK) and colour flow duplex ultrasound (Philips IU22; Philips Healthcare, USA).
|
30 mins with 10 min washouts
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arthur Tucker, BSc PhD, St. Bartholomew's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (ACTUAL)
April 1, 2012
Study Registration Dates
First Submitted
November 5, 2013
First Submitted That Met QC Criteria
November 5, 2013
First Posted (ESTIMATE)
November 11, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
November 11, 2013
Last Update Submitted That Met QC Criteria
November 5, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- THRIVE-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
MinaPharm PharmaceuticalsRecruitingProphylaxis of Deep Vein ThrombosisEgypt
-
University of Kansas Medical CenterPenumbra Inc.CompletedAcute Deep Vein ThrombosisUnited States
-
BayerRecruitingThrombolysis | Symptomatic Proximal Deep Vein ThrombosisBelgium, France, Italy, Netherlands, Canada, Germany, Czechia
-
Oregon Health and Science UniversityTerminated
Clinical Trials on geko
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
Firstkind LtdNational Institute for Health Research, United Kingdom; University of California and other collaboratorsRecruitingDeep Vein Thrombosis | Venous Thromboembolism | Stroke, Acute | Pulmonary EmbolismUnited Kingdom
-
Firstkind LtdRecruitingEdema | SurgerySpain, United States, United Kingdom
-
Firstkind LtdActive, not recruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Wound | Arterial Leg UlcerUnited Kingdom, United States
-
Firstkind LtdCompletedStroke | Wound Heal | Cardiac Pacemaker Electrical Interference | Edema LegUnited Kingdom
-
Lawson Health Research InstituteWithdrawn
-
University Hospital Southampton NHS Foundation...CompletedDeep Vein ThrombosisUnited Kingdom
-
Lawson Health Research InstituteCompletedEdema | Kidney Transplant | Kidney Pancreas TransplantCanada
-
University College, LondonCompletedMultiple Sclerosis | Overactive BladderUnited Kingdom